OPTN - OptiNose GAAP EPS of -$0.31 revenue of $14.76M; issues FY22 guidance

OptiNose press release (NASDAQ:OPTN): Q1 GAAP EPS of -$0.31. Revenue of $14.76M (+23.4% Y/Y). The Company had cash and cash equivalents of $91.4 million as of March 31, 2022. Corporate Guidance:  The Company expects XHANCE net revenues for the full year of 2022 to be at least $90 million. In addition, the Company expects full year 2022 XHANCE average net revenue per prescription to be at least $220. Previously the Company expected full year 2022 XHANCE average net revenue per prescription to be at least $210. The Company expects total GAAP operating expenses (selling, general & administrative expenses and research & development expenses) for 2022 to be in the range of $135 - $140 million, of which the Company expects stock-based compensation to be approximately $10 million. The Company expects top-line results from ReOpen2, the second its two clinical trials evaluating XHANCE as a potential treatment for chronic sinusitis, in

For further details see:

OptiNose GAAP EPS of -$0.31, revenue of $14.76M; issues FY22 guidance